Acurx Pharmaceuticals Announces Publication in ASM Confirming DNA Pol IIIC Inhibitor Pipeline Data Showing Potential Microbiome-Sparing Class Effect
NASDAQ:ACXP Overview Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life-threatening bacterial infections, announced publication in the ASM (American Society for Microbiology) Microbiology Spectrum journal of results of a study entitled: The effects of novel oral preclinical